BIT Capital’s Y-mAbs Therapeutics YMAB Stock Holding History

BIT Capital’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,000	Closed	-$83.2K	–	173
2022 Q1	$83.2K	Buy	+7,000	New	+$71.9K	0.01%	109

Other funds holding YMAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

BIT Capital's YMAB Position: Q2 2022 in Review

BIT Capital sold out of Y-mAbs Therapeutics (YMAB) in Q2 2022, closing a stake of 7,000 shares — an estimated $83.2K sold.

BIT Capital first reported a position in YMAB in Q1 2022 and held it in 1 quarter. The position peaked at $83.2K in Q1 2022. 91 funds tracked by Wall St. Rank hold YMAB as of Q2 2022.

BIT Capital reported no remaining Y-mAbs Therapeutics position as of Q2 2022 after selling out during the quarter.
BIT Capital sold 7,000 Y-mAbs Therapeutics shares in Q2 2022, an estimated $83.2K.
BIT Capital first reported a position in Y-mAbs Therapeutics in Q1 2022 and held it in 1 quarter.
BIT Capital's Y-mAbs Therapeutics position peaked at $83.2K in Q1 2022.
91 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2022.

Based on BIT Capital's 13F filing for Q2 2022, filed 12 Feb 2025.